Unlocking the potential of gene therapy for patients with rare and orphan diseases

About Medgenics

At Medgenics, we share one singular focus - to transform the lives of our patients through the development of innovative and best-in-class therapies. We are dedicated to developing our unique technology platform (TARGT) for the express purpose of treating patients with rare and orphan diseases.


TARGT has demonstrated several advantages over current gene or protein therapy, including efficacy, safety and capital efficiency.

Latest News

04-17-15 Medgenics Reports First Quarter 2015 Financial Results 04-02-15 Medgenics to Host Conference Call to Announce First Quarter 2015 Results on April 17, 2015 03-02-15 Medgenics to Present at Upcoming Investor Conferences